Vanguard Group’s Actuate Therapeutics ACTU Stock Holding History

Vanguard Group’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$3.24M	Buy	529,111 +213,101	+67%	+$1.46M	﹤0.01%	3410
2025 Q3	$2.11M	Buy	316,010 +51,546	+19%	+$374K	﹤0.01%	3562
2025 Q2	$1.62M	Buy	264,464 +245,890	+1,324%	+$2.15M	﹤0.01%	3601
2025 Q1	$126K	Buy	18,574 +4,278	+30%	+$34.3K	﹤0.01%	4113
2024 Q4	$114K	Buy	+14,296	New	+$117K	﹤0.01%	4158

Other funds holding ACTU

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Vanguard Group's ACTU Position: Q4 2025 in Review

Vanguard Group increased its Actuate Therapeutics (ACTU) stake by 67% in Q4 2025, buying an estimated $1.46M and bringing the position to 529,111 shares worth $3.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3410.

Vanguard Group first reported a position in ACTU in Q4 2024 and has held it in 5 quarters since. 45 funds tracked by Wall St. Rank hold ACTU as of Q4 2025.

Vanguard Group held 529,111 shares of Actuate Therapeutics worth $3.24M as of Q4 2025.
Vanguard Group bought 213,101 Actuate Therapeutics shares in Q4 2025, an estimated $1.46M.
Actuate Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3410 holding.
Vanguard Group first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 5 quarters since.
45 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.